[go: up one dir, main page]

MY154715A - Anti-nr10 antibody and use thereof - Google Patents

Anti-nr10 antibody and use thereof

Info

Publication number
MY154715A
MY154715A MYPI2010002989A MYPI20102989A MY154715A MY 154715 A MY154715 A MY 154715A MY PI2010002989 A MYPI2010002989 A MY PI2010002989A MY PI20102989 A MYPI20102989 A MY PI20102989A MY 154715 A MY154715 A MY 154715A
Authority
MY
Malaysia
Prior art keywords
antibodies
antibody
present
pharmaceuticals
treating
Prior art date
Application number
MYPI2010002989A
Inventor
Kuramochi Taichi
Kasutani Keiko
Ohyama Souhei
Tsunoda Hiroyuki
Igawa Tomoyuki
Tachibana Tatsuhiko
Shiraiwa Hirotake
Esaki Keiko
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2008/072152 external-priority patent/WO2009072604A1/en
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MY154715A publication Critical patent/MY154715A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

THE PRESENT INVENTORS SUCCESSFULLY OBTAINED ANTI-NR10 ANTIBODIES HAVING AN EFFECTIVE NEUTRALIZING ACTIVITY AGAINST NR10. THE ANTI-NR10 ANTIBODIES PROVIDED BY THE PRESENT INVENTION ARE USEFUL AS, FOR EXAMPLE, PHARMACEUTICALS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES.
MYPI2010002989A 2008-12-05 2009-12-04 Anti-nr10 antibody and use thereof MY154715A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2008/072152 WO2009072604A1 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
PCT/JP2009/054941 WO2010064456A1 (en) 2008-12-05 2009-03-13 Anti-nr10 antibodies and utilization of the same

Publications (1)

Publication Number Publication Date
MY154715A true MY154715A (en) 2015-07-10

Family

ID=42234508

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010002989A MY154715A (en) 2008-12-05 2009-12-04 Anti-nr10 antibody and use thereof

Country Status (5)

Country Link
KR (1) KR20160062207A (en)
MY (1) MY154715A (en)
SI (1) SI2354161T1 (en)
TW (1) TWI432209B (en)
WO (1) WO2010064456A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (en) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedure to control the blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CL2008002886A1 (en) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it.
TWI544077B (en) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
WO2010107110A1 (en) 2009-03-19 2010-09-23 中外製薬株式会社 Antibody constant region variant
WO2014208645A1 (en) * 2013-06-28 2014-12-31 中外製薬株式会社 Method for predicting response of patient with pruiritic disease to il-31 antagonist therapy
RU2749512C2 (en) 2015-04-14 2021-06-11 Чугаи Сейяку Кабусики Кайся Pharmaceutical composition for prevention and/or treatment of atopic dermatitis, including il-31 antagonist as the active ingredient
JP6845973B1 (en) 2019-11-20 2021-03-24 中外製薬株式会社 Antibody-containing preparation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
ATE283926T1 (en) * 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk ANTIBODIES AGAINST THE ALPHA CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
WO2000075314A1 (en) * 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor protein nr10
US20040223970A1 (en) * 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
EP1605974B1 (en) * 2003-03-04 2014-11-12 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
EP2476705B1 (en) * 2004-12-28 2015-10-07 Innate Pharma Monoclonal antibodies against NKG2A
JP2008530132A (en) * 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Method for treating skin disorders using IL-31RA antagonists
PE20061323A1 (en) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp ANTIBODIES TARGETED AGAINST AMYLOID BETA PEPTIDE AND METHODS USING THEM
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
PE20080333A1 (en) * 2006-06-08 2008-06-15 Chugai Pharmaceutical Co Ltd AGENTS TO PREVENT OR TREAT INFLAMMATORY DISEASES
US7858756B2 (en) * 2006-06-15 2010-12-28 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
US7919594B2 (en) * 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
CN101687925B (en) * 2007-02-23 2012-10-31 先灵公司 Engineered anti-IL-23p19 antibodies
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
EP2206775B1 (en) * 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody

Also Published As

Publication number Publication date
SI2354161T1 (en) 2015-12-31
TW201028165A (en) 2010-08-01
TWI432209B (en) 2014-04-01
KR20160062207A (en) 2016-06-01
WO2010064456A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
MY177564A (en) Anti-nr10 antibody and use thereof
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
MY154715A (en) Anti-nr10 antibody and use thereof
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EA200900781A1 (en) 4-PHENYPYRANE-3,5-DIONA, 4-PHENYLTIOPYRANE-3,5-DIONA AND CYCLOHEXANTHRION, AS NEW HERBICIDES
EA201490029A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
UA111818C2 (en) ANTIBODY AGAINST CSF-1R
JO2872B1 (en) New Compounds
MX2009004047A (en) Organic compounds.
TW200626171A (en) Fixed dosing of HER antibodies
WO2012116246A3 (en) Pesticidal compostions and processes related thereto
EA201291107A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
TN2010000213A1 (en) Wise binding antibodies and epitopes
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
EA201170227A1 (en) ИМИДАЗОЛКАРБОКСАМИДЫ
BRPI0906478B8 (en) anti-nr10 antibody, its use and pharmaceutical composition comprising it
ATE488232T1 (en) P53 ACTIVATE BENZOYL UREA AND BENZOYLTHIOUREA COMPOUNDS
EA201000903A1 (en) ANTITEL TO PCRV-ANTIGEN PSEUDOMONAS AERUGINOSA
WO2012166626A8 (en) Reagents and methods for treating dental disease
WO2008112659A3 (en) Regulation of osteopontin
EA200971068A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
MX2014000531A (en) Methods and compositions for treating asthma using anti-il-13 antibodies.
EP3988673A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease